Experimental drug for cholesterol and fatty liver studied in early trial
NCT ID NCT06007651
First seen Apr 17, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This early-stage study tested a new drug called LY3885125 in people with high cholesterol (dyslipidemia) and fatty liver disease (NAFLD). The main goal was to check if the drug is safe and how the body processes it. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Worldwide Clinical Trials, Inc.
San Antonio, Texas, 78217, United States
Conditions
Explore the condition pages connected to this study.